Search

Copyright of Journal of Guilan University of Medical Sciences is the property of Journal of Guilan University of Medical Sciences and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Context: Non-alcoholic fatty liver disease (NAFLD) is progressing considerably worldwide. Identifying the risk factors of NAFLD is a critical step in preventing its progression. Methods: In November 2022, two independent researchers studied seven databases, including PubMed, ISI/WoS, ProQuest, Scopus, SID, Magiran, and Google Scholar, and reference list of relevant articles, searching studies that assessed NAFLD risk factors in the Iranian adult population. Heterogeneity between studies was assessed by Cochran's test and its composition using I² statistics. A random-effects model was used when heterogeneity was observed; otherwise, a fixed-effects model was applied. Egger's regression test and Trim-and-Fill analysis were used to assess publication bias. Comprehensive Meta-analysis software (version 3) was used for the analyses of the present study. Results: The results of this study showed significant associations between NAFLD with age (n = 15, odds ratio (OR) = 2.12,95% CI: 1.79 - 2.51), body mass index (n = 46, OR= 5.00,95% CI: 3.34 - 7.49), waist circumference (n = 20, OR = 6.37,95% CI: 3.25 -12.48), waist-to-hip ratio (n = 17, OR = 4.72, 95% CI: 3.93 - 5.66), total cholesterol (n = 39, OR = 1.80, 95% CI: 1.52 - 2.13), high-density lipoprotein (n = 37, OR = 0.53, 95% CI: 0.44-0.65), low-density lipoprotein (n = 31, OR = 1.68, 95% CI: 1.38 - 2.05), triglyceride (n = 31, OR = 3.21, 95% CI: 2.67-3.87), alanine aminotransferase (n = 26, OR = 4.06,95% CI: 2.94 - 5.62), aspartate aminotransferase (n = 27, OR = 2.16,95% CI: 1.50-3.12), hypertension (n =13, OR = 2.53,95% CI: 2.32 - 2.77), systolic blood pressure (n = 13, OR = 1.83,95% CI: 1.53 - 2.18), diastolic blood pressure (n = 14, OR=1.80,95% CI: 1.48-2.20), fasting blood sugar (n = 31, OR=2.91,95% CI: 2.11-4.01), homeostatic model assessment for insulin resistance (n = 5, OR = 1.92,95% CI: 1.48 - 2.59), diabetes mellitus (n =15, OR = 3.04,95% CI: 2.46-3.75), metabolic syndrome (n = 10, OR = 3.56,95% CI: 2.79 - 4.55), and physical activity (n = 11, OR= 0.32, 95% CI: 0.24-0.43) (P< 0.05). Conclusions: In conclusion, several factors are significantly associated with NAFLD. However, anthropometric indices had the strongest relationship with NAFLD in the Iranian adult population. [ABSTRACT FROM AUTHOR]

Background: Most data on the effect of inflammatory bowel disease (IBD) and its treatments on coronavirus disease 2019 (COVID-19) outcomes have not had non-IBD comparators. Hence, we aimed to describe COVID-19 outcomes in IBD compared to non-IBD patients. Methods: We conducted a prospective cohort study of registered IBD patients with confirmed COVID-19 from six provinces in Iran from February to April 2020. Proven COVID-19 patients were followed up at four weeks and the frequency of outcomes was assessed. Multivariable logistic regression was used to assess associations between demographics, clinical characteristics and COVID-19 outcomes. Results: Overall, 2159 IBD patients and 4721 household members were enrolled, with 84 (3.9%) and 49 (1.1%) participants having confirmed COVID-19, respectively. Household spread of COVID-19 was not common in this cohort (1.2%). While hospitalization was significantly more frequent in IBD patients compared with non-IBD household members (27.1% vs. 6.0%, P = 0.002), there was no significant difference in the frequency of severe cases. Age and presence of IBD were positively associated with hospitalization in IBD compared with non-IBD household members (OR: 1.06, 95% CI: 1.03-1.10; OR: 5.7, 95% CI: 2.0216.07, respectively). Age, presence of new gastrointestinal symptoms, and 5-aminosalicylic acid (5-ASA) use were associated with higher hospitalization rate in IBD patients (OR: 1.13, 95% CI: 1.05-1.23; OR: 6.49, 95% CI: 1.87-22.54; OR: 6.22, 95% CI: 1.90-20.36, respectively). Anti-tumor necrosis factor (TNF) was not associated with more severe outcomes. Conclusion: Age, presence of new gastrointestinal symptoms and use of 5-ASA were associated with increased hospitalization rate among IBD patients, while anti-TNF therapy had no statistical association. [ABSTRACT FROM AUTHOR]